The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 15)
Therapeutic Pipeline Program, 2017
The Parkin protein (encoded by the PARK2 gene that is linked to Parkinson's), has been shown to exert potent neuroprotective effects that could potentially be used to treat Parkinson's disease (PD). Cellivery has developed a recombinant cell-permeable Parkin protein (iCP-Parkin) using macromolecule intracellular transduction technology (MITT), a technique that can deliver active Pa...
Research Grant, 2017
Promising Outcomes of Original Grant:
Mitophagy is a cellular process during which damaged mitochondria, or energy generators, are broken down. Mitophagy has been suspected to malfunction in Parkinson's disease (PD), but evidence to support this does not exist. Using our new pre-clinical model, we have proven that mitophagy does take place in healthy brain cells but does not require a series of che...
Researchers: Ian G. Ganley, PhD
Target Validation Awards Spring 2016, 2016
Failure in the quality control of mitochondria (power houses of the cell) in neurons may contribute to Parkinson's disease (PD). Parkin is an enzyme that tags proteins from damaged mitochondria with ubiquitin (a small protein) to promote their degradation (break down). Mutations in Parkin contribute to some forms of PD. Parkin adopts an inactive conformation (structure) in the con...
Researchers: Kalle Gehring, PhD
Research Grant, 2016
The PARK2 gene encodes the Parkin protein. It is one of three genes that protect from young-onset Parkinson disease (PD); in Parkin's absence, symptoms and signs usually begin before the age of forty. Despite the gene's discovery in 1998 by Kitada et al., few Parkin-specific antibodies exist. The antibodies available do not readily detect specific, modified forms of Parkin and high...
Research Grant Supplement, 2015
This project aims to develop potent small molecule activators of Parkin, which is mutated in some forms of familial Parkinson's disease and might also be inactivated in sporadic disease. Together with PINK1, Parkin is responsible for the destruction of harmful damaged mitochondria. Our ultimate goal is to develop activators of Parkin's enzymatic functions and to te...
Researchers: Wolfdieter Springer, PhD